Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Case Report

Published on 13 Feb 2023

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report

in Cancer Molecular Targets and Therapeutics

Junhui Wang
Huijuan He
Wansu Xu
Jianxin Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1010871

1,606 views
2 citations

Original Research

Published on 10 Feb 2023

High GNG4 predicts adverse prognosis for osteosarcoma: Bioinformatics prediction and experimental verification

in Cancer Molecular Targets and Therapeutics

Xiaohong Jiang
Fuxing Tang
Junlei Zhang
Mingwei He
Tianyu Xie
Haijun Tang
Jianhong Liu
Kai Luo
Shenglin Lu
Yun Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.991483

3,298 views
1 citation

Case Report

Published on 09 Feb 2023

Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

in Cancer Molecular Targets and Therapeutics

Elise F. Nassif
Cissimol P. Joseph
Rossana Lazcano
Jocelyn T. Joseph
Prapassorn Thirasastr
Alexander J. Lazar
Neeta Somaiah

Frontiers in Oncology

doi 10.3389/fonc.2023.1046442

1,772 views
1 citation

Original Research

Published on 09 Feb 2023

GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers

in Cancer Molecular Targets and Therapeutics

Qingyi Hu
Jiaoshun Chen
Wen Yang
Ming Xu
Jun Zhou
Jie Tan
Tao Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.990551

5,629 views
13 citations

Clinical Trial

Published on 09 Feb 2023

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

in Cancer Molecular Targets and Therapeutics

Paolo A. Ascierto
Eleonora Cioli
Vanna Chiarion-Sileni
Pietro Quaglino
Francesco Spagnolo
Massimo Guidoboni
Michele Del Vecchio
Ketty Peris
Paola Queirolo
Luisa Fioretto

Frontiers in Oncology

doi 10.3389/fonc.2023.1107307

2,945 views
1 citation

Original Research

Published on 08 Feb 2023

CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma

in Cancer Molecular Targets and Therapeutics

Shen Xue
Xiao-min Su
Li-na Ke
Yu-gang Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.1077780

3,646 views
7 citations

Original Research

Published on 08 Feb 2023

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models

in Cancer Molecular Targets and Therapeutics

Daniel J. Sisler
Trista K. Hinz
Anh T. Le
Emily K. Kleczko
Raphael A. Nemenoff
Lynn E. Heasley

Frontiers in Oncology

doi 10.3389/fonc.2023.1094123

6,264 views
7 citations

Original Research

Published on 06 Feb 2023

A novel Cuprotosis-related signature predicts the prognosis and selects personal treatments for melanoma based on bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Bingqian Hu
Alphonse Houssou Hounye
Zheng Wang
Min Qi
Jianglin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1108128

3,011 views
2 citations

Review

Published on 02 Feb 2023

Relationship between NUDT21 mediated alternative polyadenylation process and tumor

in Cancer Molecular Targets and Therapeutics

Shan Xiao
Huan Gu
Li Deng
Xiongtao Yang
Dan Qiao
Xudong Zhang
Tian Zhang
Tao Yu

Frontiers in Oncology

doi 10.3389/fonc.2023.1052012

3,624 views
5 citations

Original Research

Published on 02 Feb 2023

Effects of plasma-derived exosomes from the normal and thin Bactrian camels on hepatocellular carcinoma and their differences at transcriptome and proteomics levels

in Cancer Molecular Targets and Therapeutics

Hongqiang Yao
Siriguleng Yu
Yuchen Luo
Ming Wang
Xiuying Wang
Siriguleng Xu
Yufei Chen
Zhifeng Xie

Frontiers in Oncology

doi 10.3389/fonc.2023.994340

2,137 views
1 citation

Original Research

Published on 02 Feb 2023

Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

in Cancer Molecular Targets and Therapeutics

Johnny Donovan
Zicheng Deng
Fenghua Bian
Samriddhi Shukla
Jose Gomez-Arroyo
Donglu Shi
Vladimir V. Kalinichenko
Tanya V. Kalin

Frontiers in Oncology

doi 10.3389/fonc.2023.1112859

3,696 views
6 citations

Original Research

Published on 01 Feb 2023

Autolysosomal activation combined with lysosomal destabilization efficiently targets myeloid leukemia cells for cell death

in Cancer Molecular Targets and Therapeutics

Harshit Shah
Metodi Stankov
Diana Panayotova-Dimitrova
Amir Yazdi
Ramachandramouli Budida
Jan-Henning Klusmann
Georg M. N. Behrens

Frontiers in Oncology

doi 10.3389/fonc.2023.999738

1,917 views
2 citations

Mini Review

Published on 01 Feb 2023

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

in Cancer Molecular Targets and Therapeutics

Liza C. Villaruz
Mark A. Socinski
Jared Weiss

Frontiers in Oncology

doi 10.3389/fonc.2023.1124167

7,684 views
16 citations

Editorial

Published on 31 Jan 2023

Editorial: Targeting redox regulation and autophagy systems for cancer therapy

in Cancer Molecular Targets and Therapeutics

Junmin Zhang
Abdelhabib Semlali
Paola Maycotte
Luciano Saso

Frontiers in Oncology

doi 10.3389/fonc.2023.1146670

1,421 views

Original Research

Published on 30 Jan 2023

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer

in Cancer Molecular Targets and Therapeutics

Shuai Han
Dongjie Jiang
Feng Zhang
Kun Li
Kun Jiao
Jingyun Hu
Haihan Song
Qin-Yun Ma
Jian Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1095313

3,256 views
5 citations

Original Research

Published on 27 Jan 2023

Identification of thioredoxin-1 as a biomarker of lung cancer and evaluation of its prognostic value based on bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Xiaoting Liu
Xilin Dong
Yaxin Hu
Yanan Fang

Frontiers in Oncology

doi 10.3389/fonc.2023.1080237

2,677 views
4 citations

Navigation group

Articles

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report

High GNG4 predicts adverse prognosis for osteosarcoma: Bioinformatics prediction and experimental verification

Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models

A novel Cuprotosis-related signature predicts the prognosis and selects personal treatments for melanoma based on bioinformatics analysis

Relationship between NUDT21 mediated alternative polyadenylation process and tumor

Effects of plasma-derived exosomes from the normal and thin Bactrian camels on hepatocellular carcinoma and their differences at transcriptome and proteomics levels

Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

Autolysosomal activation combined with lysosomal destabilization efficiently targets myeloid leukemia cells for cell death

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

Editorial: Targeting redox regulation and autophagy systems for cancer therapy

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer

Identification of thioredoxin-1 as a biomarker of lung cancer and evaluation of its prognostic value based on bioinformatics analysis